References
- Hanahan D, Weinberg RA. Review hallmarks of cancer : The next generation. Cell [Internet]. 2011;144:646–74. Available from: doi:10.1016/j.cell.2011.02.013.
- Greaves M, Maley CC. Clonal evolution in cancer. Nature [Internet]. 2012 [cited 2014 Jul 9];481:306–13. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3367003&tool=pmcentrez&rendertype=abstract doi:10.1038/nature10762.
- Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife [Internet]. 2013 [cited 2016 Feb 23];2:e00747. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3691570&tool=pmcentrez&rendertype=abstract.
- Sawyers C. Targeted cancer therapy. Nature [Internet]. 2004 [cited 2017 Mar 24];432:294–7. Available from: http://www.nature.com/doifinder/10.1038/nature03095 doi:10.1038/nature03095.
- Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol [Internet]. 2015 [cited 2018 Apr 5];16:1473–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26482279 doi:10.1016/S1470-2045(15)00290-9.
- Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol [Internet]. 2010 [cited 2018 Jan 2];7:455–65. Available from: http://www.nature.com/doifinder/10.1038/nrclinonc.2010.82 doi:10.1038/nrclinonc.2010.82.
- Yaghmour G, Pandey M, Ireland C, Patel K, Nunnery S, Powell D, Baum S, Wiedower E, Schwartzberg LS, Martin MG. Role of genomic instability in immunotherapy with checkpoint inhibitors. Anticancer Res [Internet]. 2016 [cited 2017 Jul 24];36:4033–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27466509.
- Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 1910;3:1–48.
- Dougan M, Dranoff G. Immune therapy for cancer. AnnuRevImmunol. 2009;27:83–117.
- Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30. doi:10.1200/JCO.2013.53.0105. PMID:24590637.
- Couzin-Frankel J. Cancer immunotherapy. Science (80-). 2013;342:1432–3. doi:10.1126/science.342.6165.1432.
- Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer [Internet]. 2016 [cited 2016 Feb 4];16:121–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26822578 doi:10.1038/nrc.2016.2.
- Barnes E. Diseases and human evolution. Albuquerque: Univ New Mex Press; 2005.
- Shi H, Sun M, Liu L, Wang Z. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Mol Cancer [Internet]. 2014 [cited 2017 Jul 24];13:219. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25241075 doi:10.1186/1476-4598-13-219.
- Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med [Internet]. 2011;3:95ra73. Available from: http://stm.sciencemag.org/content/3/95/95ra73.full.
- Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med [Internet]. 2013;368:1509–18. Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215134 doi:10.1056/NEJMoa1215134.
- Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. How I Treat: Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–96. doi:10.1182/blood-2014-05-552729. PMID:24876563.
- Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, Liang B, Luo Y, Shi J, Jin A, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol [Internet]. 2016;9:70. Available from: http://jhoonline.biomedcentral.com/articles/10.1186/s13045-016-0299-5 doi:10.1186/s13045-016-0299-5.
- Davila ML, Riviere I, Wang X, Bartido S, Park J, Chung SS, Stefanski J, Borquez-ojeda O, Qu J, Wasielewska T, et al. Efficacy and toxicity management of 19–28z CAR T Cell therapy in B Cell acute lymphoblastic leukemia. Sci Transl Med. 2015;6:224ra25.
- Lacerda-Queiroz N, Lima OCO, Carneiro CM, Vilela MC, Teixeira AL, Carvalho AT, Araújo MSS, Martins-Filho OA, Braga ÉM, Carvalho-Tavares J. Plasmodium berghei NK65 induces cerebral leukocyte recruitment in vivo: An intravital microscopic study. Acta Trop [Internet]. 2011;120:31–9. Available from: doi:10.1016/j.actatropica.2011.04.020.
- Bao LQ, Huy NT, Kikuchi M, Yanagi T, Senba M, Shuaibu MN, Honma K, Yui K, Hirayama K. CD19(+) B Cells confer protection against experimental cerebral malaria in semi-immune rodent model. PLoS One. 2013;8:1–13. doi:10.1371/journal.pone.0064836.
- Mutnal MB, Hu S, Schachtele SJ, Lokensgard JR. Infiltrating regulatory B cells control neuroinflammation following viral brain infection. J Immunol [Internet]. 2014 [cited 2017 Jul 24];193:6070–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25385825 doi:10.4049/jimmunol.1400654.
- Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res [Internet]. 1989 [cited 2018 Apr 6];49:2857–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2720646.
- Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: Potential for improved immunotherapy. Blood. 2002;99:2009–16. doi:10.1182/blood.V99.6.2009. PMID:11877273.
- Murphy A, Westwood JA, Brown LE, Teng MWL, Moeller M, Xu Y, Smyth MJ, Hwu P, Darcy PK, Kershaw MH. Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther [Internet]. 2007;14:499–508. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17332777 doi:10.1038/sj.cgt.7701034.
- Heemskerk M, Hoogeboom M, Hagedoorn R, Kester M, Willemze R, Falkenburg J. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med [Internet]. 2004;199:885–94. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15051765%5Cnpapers3://publication/uuid/DB3D1BCB-2CA5-4F15-A871-226C5E66766B doi:10.1084/jem.20031110.
- Balfour HH, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of epstein-barr virus infection among individuals aged 6–19 Years in the united states and factors affecting its acquisition. J Infect Dis [Internet]. 2013 [cited 2017 Jun 22];208:1286–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23868878 doi:10.1093/infdis/jit321.
- Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science (80-). 2015;348:74–80. doi:10.1126/science.aaa6204.
- Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol [Internet]. 2013;14:1014–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24048123 doi:10.1038/ni.2703.
- McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (80-) [Internet]. 2016 [cited 2017 Dec 23];351:1463–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26940869 doi:10.1126/science.aaf1490.
- Xin G, Schauder DM, Jing W, Jiang A, Joshi NS, Johnson B, Cui W. Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. Proc Natl Acad Sci [Internet]. 2017:201614315. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1614315114.
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (80-). 1996;271:1734–6. doi:10.1126/science.271.5256.1734.
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med [Internet]. 2010 [cited 2017 Jul 25];363:711–23. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1003466 doi:10.1056/NEJMoa1003466.
- Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039–47. doi:10.1158/1078-0432.CCR-11-1823. PMID:22271879.
- Bertrand A, Kostine M, Barnetche T, Truchetet M-E, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Biol [Internet]. 2013;11:EE. Available from: https://doi.org/10.1186/s12916-015-0455-8.
- Gong JH, Zhang M, Modlin RL, Linsley PS, Iyer D, Lin Y, Barnes PF. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect Immun. 1996;64:913–8. PMID:8641800.
- Flynn JL, Chan J. Tuberculosis : Latency and reactivation. Infect Immun. 2001;69:4195–201. doi:10.1128/IAI.69.7.4195-4201.2001. PMID:11401954.
- Gontero P, Bohle A, Malmstrom P-U, O'Donnell MA, Oderda M, Sylvester R, Witjes F. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol [Internet]. 2010 [cited 2015 Oct 2];57:410–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19969411 doi:10.1016/j.eururo.2009.11.023.
- Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 Blockade with CpG Therapy. J Immunother [Internet]. 2010 [cited 2017 Aug 13];33:225–35. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002371-201004000-00001 doi:10.1097/CJI.0b013e3181c01fcb.
- Sprent J, Surh CD. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nat Immunol [Internet]. 2011 [cited 2018 Jan 2];12:478–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21739670 doi:10.1038/ni.2018.
- Topalian SL, Hodi FS, Brahmer JR, Al E. Safety, activity, and immune correlates of Anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:339–54. doi:10.1056/NEJMoa1200690. PMID:22276823.
- Filskov Sorensen S, Zhou W, Dolled-Filhart M, Baehr Georgsen J, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P, Hager H. PD-L1 Expression and survival among patients with advanced Non–small cell lung cancer treated with chemotherapy 1. Transl Oncol [Internet]. 2016 [cited 2018 Jan 19];9:64–9. Available from: https://ac.els-cdn.com/S1936523315300528/1-s2.0-S1936523315300528-main.pdf?_tid=5d9c545e-fcf4-11e7-927e-00000aacb35d&acdnat=1516351393_1a215b344e196e485a99260ba0f5d24e doi:10.1016/j.tranon.2016.01.003.
- Ma K, Wei X, Dong D, Wu Y, Geng Q, Li E. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett [Internet]. 2017 [cited 2018 Jan 19];14:250–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28693161 doi:10.3892/ol.2017.6105.
- Zhao T, Li C, Wu Y, Li B, Zhang B. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. PLoS One [Internet]. 2017 [cited 2018 Jan 2];12:e0176822. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28453554 doi:10.1371/journal.pone.0176822.
- Salazar M d'A, Manuel ER, Tsai W, D'Apuzzo M, Goldstein L, Blazar BR, Diamond DJ. Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. Oncoimmunology. 2016;5:e1160184.
- Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol [Internet]. 2007 [cited 2017 Aug 13];8:239–45. Available from: http://www.nature.com/doifinder/10.1038/ni1443 doi:10.1038/ni1443.
- Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M, Goodier MR. PD-1 expression on natural killer cells and CD8 + T cells during chronic HIV-1 infection. Viral Immunol [Internet]. 2012;25:329–32. Available from: http://online.liebertpub.com/doi/abs/10.1089/vim.2011.0096 doi:10.1089/vim.2011.0096.
- Alvarez IB, Pasquinelli V, Jurado JO, Abbate E, Musella RM, de la Barrera SS, García VE. Role played by the programmed death‐1–Programmed death ligand pathway during innate immunity against mycobacterium tuberculosis. J Infect Dis [Internet]. 2010;202:524–32. Available from: http://jid.oxfordjournals.org/lookup/doi/10.1086/654932 doi:10.1086/654932.
- Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, Goldufsky JW, Hughes T, Zayas JP, Dolubizno H, et al. Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death. Cell Rep. 2016;17:957–65. doi:10.1016/j.celrep.2016.09.068. PMID:27760326.
- Fuse S, Tsai C-Y, Molloy MJ, Allie SR, Zhang W, Yagita H, Usherwood EJ. Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1. J Immunol [Internet]. 2009;182:4244–54. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2713929&tool=pmcentrez&rendertype=abstract doi:10.4049/jimmunol.0802041.
- Iheagwara UK, Beatty PL, Van PT, Ross TM, Minden JS, Finn OJ. Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor associated antigens : A new view of cancer immunosurveillance. Cancer Immunol Res. 2015;2:263–73. doi:10.1158/2326-6066.CIR-13-0125.
- Michaud H-A, Eliaou J-F, Lafont V, Bonnefoy N, Gros L. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. Oncoimmunology [Internet]. 2014 [cited 2018 Jan 2];3:e955684. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25941618 doi:10.4161/21624011.2014.955684.
- They L, Michaud H-A, Becquart O, Lafont V, Guillot B, Boissière-Michot F, Jarlier M, Mollevi C, Eliaou J-F, Bonnefoy N, et al. PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody. Oncoimmunology [Internet]. 2017 [cited 2018 Jan 2];6:e1353857. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29123966 doi:10.1080/2162402X.2017.1353857.
- Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med [Internet]. 2015;372:724–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25693012 doi:10.1056/NEJMoa1413513.
- Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 2014;25:1544–50. doi:10.1093/annonc/mdu112. PMID:24608200.
- Nava-Parada P, Forni G, Knutson K. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res [Internet]. 2007;67:1326–34. Available from: http://cancerres.aacrjournals.org/content/67/3/1326.short doi:10.1158/0008-5472.CAN-06-3290.
- Charlebois R, Allard B, Allard D, Buisseret L, Turcotte M, Pommey S, Chrobak P, Stagg J. PolyI:C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors. Cancer Res. 2016;77:312–9. PMID:27872096.
- Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci [Internet]. 2011 [cited 2017 Aug 13];108:7142–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21482773 doi:10.1073/pnas.1016569108.
- Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology [Internet]. 1996;219:339–49. Available from: http://www.sciencedirect.com/science/article/pii/S0042682296902597 doi:10.1006/viro.1996.0259.
- Chaung HC. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int Immunopharmacol. 2006;6:1586–96. doi:10.1016/j.intimp.2006.06.001. PMID:16919831.
- Chu CM, Sheen IS, Yeh CT, Hsieh SY, Tsai SL, Liaw YF. Serum levels of interferon-alpha and -gamma in acute and chronic hepatitis B virus infection. Dig Dis Sci [Internet]. 1995 [cited 2017 Aug 13];40:2107–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7587774 doi:10.1007/BF02208991.
- Netea MG, Joosten LAB, Latz E, Mills KHG, Natoli G, Stunnenberg HG, ONeill LAJ, Xavier RJ. Trained immunity: A program of innate immune memory in health and disease. Science (80-) [Internet]. 2016 [cited 2018 Jan 25];352:aaf1098-aaf1098. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27102489.
- Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol [Internet]. 2012 [cited 2014 Jul 9];30:658–70. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3888062&tool=pmcentrez&rendertype=abstract doi:10.1038/nbt.2287.
- Bell J, McFadden G. Viruses for tumor therapy. Cell Host Microbe [Internet]. 2014 [cited 2014 Oct 29];15:260–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24629333 doi:10.1016/j.chom.2014.01.002.
- Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, Préville X, Quéméneur E, Kepp O, Adam J, et al. Immune checkpoint blockade, immunogenic chemotherapy or IFN-α Blockade boost the local and abscopal effects of oncolytic virotherapy. Cancer Res [Internet]. 2017 [cited 2018 Jan 2];77:4146–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28536278 doi:10.1158/0008-5472.CAN-16-2165.
- Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O'Connor MK, Kyle RA, Leung N, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc [Internet]. 2014 [cited 2014 Oct 8];89:926–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24835528 doi:10.1016/j.mayocp.2014.04.003.
- Ledford H. Cancer-fighting viruses near market. Nature. 2015:526.
- Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother cancer [Internet]. 2016;4:53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27660707%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5029010 doi:10.1186/s40425-016-0158-5.
- Kaufman HL, Wang W, Manola J, DiPaola RS, Ko Y-J, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the eastern cooperative oncology group. J Clin Oncol. 2004;22:2122–32. doi:10.1200/JCO.2004.08.083. PMID:15169798.
- Villumsen M, Sørup S, Jess T, Ravn H, Relander T, Baker JL, Benn CS, Sørensen TIa, Aaby P, Roth A. Risk of lymphoma and leukaemia after bacille Calmette-Guérin and smallpox vaccination: a Danish case-cohort study. Vaccine [Internet]. 2009 [cited 2015 Apr 21];27:6950–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19747577 doi:10.1016/j.vaccine.2009.08.103.
- Mastrangelo G, Krone B, Fadda E, Buja A, Grange JM, Rausa G, de Vries E, Koelmel KF. Does yellow fever 17D vaccine protect against melanoma? Vaccine [Internet]. 2009 [cited 2015 Apr 21];27:588–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19010368 doi:10.1016/j.vaccine.2008.10.076.
- Grange JM, Stanford JL, Stanford CA, Ko KF. Vaccination strategies to reduce the risk of leukemia and melanoma. J R Soc Med. 2003;96:389–92. doi:10.1177/014107680309600806. PMID:12893854.
- Krone B, Kölmel KF, Henz BM, Grange JM. Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: An epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer [Internet]. 2005 [cited 2015 Apr 21];41:104–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15617995 doi:10.1016/j.ejca.2004.08.010.
- Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res [Internet]. 2002 [cited 2017 Jul 24];62:5510–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12359761.
- Kölmel KF, Grange JM, Krone B, Mastrangelo G, Rossi CR, Henz BM, Seebacher C, Botev IN, Niin M, Lambert D, et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European organization for research and treatment of cancer cohort study on 542 patients. Eur J Cancer [Internet]. 2005 [cited 2015 Apr 21];41:118–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15617996 doi:10.1016/j.ejca.2004.09.023.
- Finn OJ, Beatty PL. Cancer immunoprevention. Curr Opin Immunol [Internet]. 2016;39:52–8. Available from: https://doi.org/10.1016/j.coi.2016.01.002 doi:10.1016/j.coi.2016.01.002.
- Hamanakai Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IGG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer. 2003;103:97–100. doi:10.1002/ijc.10801. PMID:12455059.
- West RO. Epidemiologic study of malignancies of the ovaries. Cancer. 1966;19:1001–7. doi:10.1002/1097-0142(196607)19:7%3c1001::AID-CNCR2820190714%3e3.0.CO;2-S. PMID:5939299.
- Menczer J, Modan M, Ranon L, Golan A. Possible role of mumps virus in the etiology of ovarian cancer. Cancer [Internet]. 1979 [cited 2018 Jan 19];43:1375–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/445337 doi:10.1002/1097-0142(197904)43:4%3c1375::AID-CNCR2820430427%3e3.0.CO;2-D.
- Cramer DW, Vitonis AF, Pinheiro SP, McKolanis JR, Fichorova RN, Brown KE, Hatchette TF, Finn OJ. Mumps and ovarian cancer: moder interpretation of an historic association. Cancer Causes Control. 2011;21:1193–201. doi:10.1007/s10552-010-9546-1.
- Deng J, Wang L, Chen H, Li L, Ma Y, Ni J, Li Y. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer Metastasis Rev. 2013;32:535–51. doi:10.1007/s10555-013-9423-y. PMID:23609751.
- Gray HJ, Benigno B, Berek J, Chang J, Mason J, Mileshkin L, Mitchell P, Moradi M, Recio FO, Michener CM, et al. Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. J Immunother Cancer [Internet]. 2016;4:34. Available from: http://jitc.biomedcentral.com/articles/10.1186/s40425-016-0137-x doi:10.1186/s40425-016-0137-x.
- Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter MD, Salazar AM, Schoen RE, Finn OJ. MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2012;100:130–4.
- Finn OJ. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res [Internet]. 2014;2:708–13. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4163937&tool=pmcentrez&rendertype=abstract doi:10.1158/2326-6066.CIR-14-0110.
- Vella L, Mina Y, Amya P, Finn OJ. Cyclin B1 vaccine delays spontaneous tumors. Ann N Y Acad Sci. 2009;144:724–32.
- Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci U S A [Internet]. 2009;106:14010–5. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2720407&tool=pmcentrez&rendertype=abstract doi:10.1073/pnas.0903225106.
- Leisenfelder SA, Moffat JF. Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity. J Virol [Internet]. 2006;80:5577–87. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1472175&tool=pmcentrez&rendertype=abstract doi:10.1128/JVI.00163-06.
- Croen KD, Ostrove JM, Dragovic LJ, Straus SE. Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci U S A [Internet]. 1988 [cited 2017 Jul 24];85:9773–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2849116 doi:10.1073/pnas.85.24.9773.
- Arvin AM. Humoral and cellular immunity to varicella‐zoster virus: An Overview. J Infect Dis [Internet]. 2008 [cited 2017 Jul 24];197:S58–60. Available from: https://academic.oup.com/jid/article-lookup/doi/10.1086/522123 doi:10.1086/522123.
- Weinberg A, Levin MJ. VZV T Cell-Mediated Immunity [Internet]. In: Current topics in microbiology and immunology. 2010 [cited 2018 Jan 19]. page 341–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20473790.
- Kleef R, Jonas WB, Knogler W, Stenzinger W. Fever, cancer incidence and spontaneous remissions. Neuroimmunomodulation. 2001;9:55–64. doi:10.1159/000049008. PMID:11549887.
- Hoption Cann SA, van Netten JP, van Netten C. Acute infections as a means of cancer prevention: opposing effects to chronic infections? Cancer Detect Prev [Internet]. 2006 [cited 2016 Apr 14];30:83–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16490323 doi:10.1016/j.cdp.2005.11.001.
- Jarmalavicius S, Welte Y, Walden P. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells. J Biol Chem. 2012;287:33401–11. doi:10.1074/jbc.M112.358903. PMID:22869377.
- Herberts CA, Van Gaans-van den Brink J, Van der Heeft E, Van Wijk M, Hoekman J, Jaye A, Poelen MCM, Boog CJP, Roholl PJM, Whittle H, et al. Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection. Hum Immunol. 2003;64:44–55. doi:10.1016/S0198-8859(02)00707-3. PMID:12507814.
- Abel U, Becker N, Angerer R, Frentzel-beyme R, Kaufmann M, Wysoeki S, Schulz G. Common infections in the history of cancer patients and controls. J Cancer Res Clin Oncol. 1991;117:339–44. doi:10.1007/BF01630717. PMID:2066354.
- Jacqueline C, Bourfia Y, Hbid H, Sorci G, Thomas F, Roche B. Interactions between immune challenges and cancer cells proliferation: timing does matter! Evol Med Public Heal. 2016; in press:299–311. doi:10.1093/emph/eow025.
- Jacqueline C, Tasiemski A, Sorci G, Ujvari B, Maachi F, Missé D, Renaud F, Ewald P, Thomas F, Roche B. Infections and cancer: the “fifty shades of immunity” hypothesis. BMC Cancer. 2017;17:257. PMID:28049525.
- Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer [Internet]. 2014 [cited 2014 Jul 10];14:559–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24990523 doi:10.1038/nrc3770.